Other variables associated with reduced overall survival included high-risk cytogenetics, age, CKD, heart disease, secondary amyloidosis, dFLC, β2-microglobulin, and treatment with proteasome inhibitors (Table 4). This evidence concerns the gene HLA-G and heart disorder.